An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Trabectedin (Primary) ; Dexamethasone
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 27 Nov 2017 Results of pooled data from two trials (NCT01273493 and NCT01343277) assessing pharmacokinetics and safety of trabectedin in patients with pre-existing hepatic impairment, were published in the Investigational New Drugs.
- 07 Jun 2016 Results related to liver toxicity of Trabectedin from OVC1004 and SAR3007 studies presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 19 May 2016 According to PharmaMar media release, results will be presented at the 52nd Congress of the American Society of Clinical Oncology (ASCO).